Pathogenesis, evaluation and treatment of hypogonadism in men;Etiopatogeneza, rozpoznawanie i leczenie hipogonadyzmu u mȩżczyzn

Endokrynologia Polska

Volumn 60, Issue 3, 2009, Pages 222-233

  Rabijewski, Michał ^a   Zgliczyński, Wojciech ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Hypogonadism; Hypophysis; Testis; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; GONADORELIN; GONADOTROPIN; TESTOSTERONE; TESTOSTERONE ESTER;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CLINICAL FEATURE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; GEL; GYNECOMASTIA; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS TUMOR; IMPOTENCE; KLINEFELTER SYNDROME; MALE; MALE INFERTILITY; PATHOGENESIS; PREPUBERTY; RECEPTOR GENE; REVIEW; SPERMATOGENESIS; VIRILIZATION;

ADULT; HUMANS; HYPOGONADISM; KLINEFELTER SYNDROME; MALE; PITUITARY NEOPLASMS; TESTOSTERONE;

EID: 67749108206     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Stedman's Medical Dictionary. Wyd. 26. Williams & Wilkins, Baltimore 1995: 836.
2. Plymate S. Hypogondism. Endocrinol Metab Clin North Am 1994; 23: 749-772.
3. Mulligan T, Frick MF, Zuraw QC i wsp. Prevalence of hypogonadism in males aged at least 45 years: The HIM Study. Int J Clin Pract 2006; 60: 762-769. (Pubitemid 43881152)
4. Rommerts FFG. Testosterone: an overview of biosynthesis, transport, metabolism and nongenomic action. W: Nieschlag E, Behre HM (red.). Testosterone - action, deficiency, substitution. Springer-Verlag 1998: 1-33.
5. Trzeciak WH. Synteza, transport i mechanizm dzialania androgenów. W: Semczuk M, Kurpisz M (red.). Andrologia, PZWL 2007: 68-88.
6. Quigley CA. The androgen receptor; physiology and pathophysiology. W: Nieschlag E, Behre HM (red.). Testosterone - action, deficiency, substitution. Springer-Verlag 1998: 33-107.
7. Canale D, Caglieresi C, Moschini CD i wsp. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clinical Endocrinol 2005; 63: 356-361.
8. Łukaszyk A. Plemnikotwórcza i dokrewna czynnoś ć ja̧dra. W: Semczuk M, Kurpisz M (red.). Andrologia. Wydawnictwo PZWL, Warszawa 2007: 31-50.
9. Dhillo WS, Chaudhri OB, Patterson M i wsp. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Andocrinol Metab 205; 90: 6609-6615.
10. Foresta C, Bettella A, Vinanzi C i wsp. Insulin-like factor 3: a novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab 2004; 89: 5952-5958. (Pubitemid 39628399)
11. Randall VA. The role of testosterone in spermatogenesis. W: Nieschlag E, Behre HM (red.). Testosterone - action, deficiency, substitution. Springer-Verlag 1998: 143-169.
12. Rabijewski M, Zgliczyński W. Hipogonadyzm u mȩżczyzn. W: Zgliczyński W, Zgliczyński S (red.). Standardy Endokrynologii. Narodowa Fundacja Endokrynologii, Warszawa 2007.
13. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocrine Practice 2002; 8: 440-456.
14. Plymate SR, Paulsen CA. Klinefelter's syndrome. W: King R, Motulsky A (red.). The Genetic Basis of Common Disease. Oxford University Press, New York 1989: 876-894.
15. Canfranco F, Kamischke A, Zitzmann M i wsp. Klinefelter's syndrome. Lancet 2004; 364: 273-283.
16. Saenger P, Reiter EO. Management of cryptorchidism. Trends Endocrinol Metab 1992; 3: 249.
17. Hardelin JP, Petit C. A molecular approach to the pathophysiology of the X chromosome-linked Kallmann's syndrome. Baillieres Clin Endocrinol Metab 1995; 9: 489-507.
18. Bhagavath B, Podolsky RH, Ozata M i wsp. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism. Fertility and Sterility 2006; 85: 706-713.
19. Layman L. The molecular basis of human hypogonadotropic hypogonadism. Mol Gen Metab 1999; 68: 191-199. (Pubitemid 29501090)
20. Wolczyński S, Laudański P, Jarza̧bek K i wsp. A case of complete hypogonadotropic hypogonadism with a mutation in the gonadotropin-releasing hormone receptor gene. Fertility and Sterility 2003; 79: 442-444.
21. Raivio T, Falardeau J, Dwyer A i wsp. Reversal of idiopathic hypogonadotropic hypogonadism. N Eng J Med 2007; 357: 863-873.
22. Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. J Urol 1989; 142: 992-994. (Pubitemid 19250748)
23. Zgliczyński W. Prolaktynoma. W: Zgliczyński W (red.). Postȩpy w rozpoznawaniu i leczeniu chorób podwzgórza i przysadki. Narodowa Fundacja Endokrynologii, Warszawa 2003: 31-42.
24. Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J Clin Endocrinol Metab 1987; 65: 585-587.
25. Warren MP, Goodman LR. Exercise-induced endocrine pathologies. J Endocrinol Invest 2003; 26: 873-878.
26. Woolf PD, Hamill RW, McDonald JV i wsp. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444-450.
27. Rochira V, Faustini-Fustini M, Balestrieri A i wsp. Estrogen replacement therapy in a men with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J Clin Endocrinol Metab 2000; 85: 1841-1845. (Pubitemid 32269286)
28. Hiort O, Holterhus PM, Horter T i wsp. Significance of mutations in the androgen receptor gen in males with idiopathic infertility. J Clin Endocrinol Metab 2000; 85: 2810-2815. (Pubitemid 32269157)
29. Harman SM, Metter EJ, Tobin JD i wsp. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724-731.
30. Kaufmann JM, Vermeulen A. The decline of androgens levels in elderly men and its clinical and therapeutic implications. Endocr Review 2005; 26: 833-876. (Pubitemid 41428540)
31. Araujo AB, O'Donnell AB, Brambilla DJ i wsp. Prevalence and incidence of androgen deficiency in middle-aged and older man: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-5926.
32. Nieschlag E, Swerdloff R, Behre HM i wsp. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. Int J Andrology 2005; 28: 125-127. (Pubitemid 40780337)
33. Bhasin S, Cunningham GR, Hayes FJ i wsp. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
34. Rabijewski M, Kubuj M, Zgliczyński S. Skuteczność i bezpieczeństwo hormonalnego leczenia zastȩpczego (HLZ) testosteronem u starszych mȩżczyzn z hipogonadyzmem. Endokrynologia Polska 2003; 3: 293-300.
35. Glass AR, Swerdloff RS, Bray GA i wsp. Low serum testosterone and sex- hormone binding globulin in massively obese men. J Clin Endocrinol Metab 1977; 45: 1211-1219.
36. Peiris A, Stagner J, Playmate S i wsp. Sex hormone-binding globulin levels in normal men: role of pulsatile insulin secretion. J Clin Endocrinol Metab 1993; 76: 279-282.
37. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672. (Pubitemid 30645223)
38. Zitzmann M, Nieschlag E. Testosterone substitution: current modalities and perspectives. J Reproduktionsmed Endokrinol 2006; 3: 109-116. (Pubitemid 43855573)
39. Zgliczyński S, Rabijewski M, Wiktorowicz-Dudek A. Wskaźnik andropauzy w rozpoznawaniu i leczeniu ujawniaja̧cego siȩ z wiekiem hipogonadyzmu. Endokrynologia Polska 2003; 2: 148-154.
40. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994; 23: 857-875.
41. Chatani F. Possible mechanism for testicular focal necrosis induced by hCG in rats. J Tox Sci 2006; 31: 291-303. (Pubitemid 44730411)
42. Dunkel L, Taskinen S, Hovatta I i wsp. Germ cell apoptosis after treatment of cryptorchism with human chorionic gonadotropin is associated with impaired reproductive function in the adult. J Clin Invest 1997; 100: 2341-2346. (Pubitemid 27500158)
43. Aulitzky W, Frick J, Galvan G. Pulsatile luteinizing hormone-releasing hormone treatment of male hypogonadotropic hypogonadism. Fertil Steril 1988; 50: 480-486. (Pubitemid 18218400)
44. Schopohl J. Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. Hum Reprod 1993; 8 (supl. 2): 175-179. (Pubitemid 23337200)
45. Behre HM, Wang C, Handelsman DJ i wsp. Pharmacology of testosterone preparations. W. Nieschlag E, Behre HM (red.). Testosterone - action, deficiency, substitution. Cambridge University Press, United Kingdom 2004: 405-444.
46. Schubert M, Minemann T, Hubler D i wsp. Intramuscular testosterone undecanoate: pharmacokineetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-5934. (Pubitemid 39518421)
47. Meikle AW, Mazer NA, Moellmer JF i wsp. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 623-628.
48. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989; 68: 369-373. (Pubitemid 19052879)
49. Parker S. Armitage M. Experience with transdermal testosterone replacement therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999; 50: 57-62. (Pubitemid 29079368)
50. Swerdloff RS, Wang C, Cunningham G i wsp. Long term pharmacokinetics of transdermal testosterone gel inhypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500-4510.
51. Wang C, Swerdloff RS, Iranmanesh A i wsp. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. (Testosterone Gel Study Group) J Clin Endocrinol Metab 2000; 85: 2839-2853. (Pubitemid 30828546)
52. Palacios A, Campfield LA, McClure RD i wsp. Effect of testosterone enanthate on hematopoiesis in normal men. Fertil Steril 1983; 40: 100-104.
53. Douglas TH, Connelly RR, McLeod DG i wsp. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246-250.
54. Behre HM, Bohmeyer J, Nieschlag E i wsp. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994; 40: 341-349.